Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer

Journal of Ovarian Research

Research

Zhongmian Pan¹  Zhongbin Luo¹  Bingbing Zhao¹  Zhijun Yang¹  Li Li¹  Yujie Chen²  Hongying He³ 

[1] Department of Gynecology and Oncology, Guangxi Medical University Cancer Hospital, 71 Hedi Road, 530021, Nanning, China;Department of Obstetrics and Gynecology, Liuzhou People’s Hospital, Liuzhou, China;Department of Obstetrics and Gynecology, Liuzhou Workers Hospital, Liuzhou, China;

关键词: Apatinib;    Advanced recurrent epithelial ovarian cancer;    Angiogenesis inhibitor;    CA125;   

DOI  :  10.1186/s13048-022-01055-4

 received in 2021-12-06, accepted in 2022-10-26,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundApatinib is an oral anti-angiogenic drug that mainly targets vascular endothelial growth factor receptor 2 (VEGFR-2) and is widely used in a variety of solid tumours. The purpose of this study is to evaluate the clinical efficacy and safety of apatinib in patients with advanced platinum-resistant relapsed epithelial ovarian cancer (EOC).MethodsA retrospective analysis was performed, the clinical data of patients with stage IIIC-IV platinum-resistant relapsed EOC between January 2014 and May 2018 were collected. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were reviewed and evaluated. The propensity score matching (PSM) method was used to determine the final case data included in this study.ResultsAccording to 1:2 propensity matching, 108 patients were finally taken into account: 36 in the apatinib group and 72 in the control group. The follow-up ended in January 2019, and the median follow-up time was 28 months. In the apatinib group, ORR was 30.56% and DCR was 66.67%, whereas in the control group, ORR was 16.67% and DCR was 44.44%. In the apatinib group, median PFS was 6.0 months (95% CI 3.69–8.31) and median OS was 15.8 months (95% CI 6.99–24.6), while in the control group, median PFS was 3.3 months (95% CI 2.44–4.16) and median OS was 9.2 months (95% CI 6.3–12.06); the difference was statistically significant (P < 0.05). Apatinib was more effective than conventional chemotherapy in reducing the risk of PFS [HR 0.40 (95% CI 0.22–0.76), P = 0.0017] and OS [HR 0.40 (95% CI 0.21–0.73), P = 0.002]. Multivariate Cox analysis showed that the course of treatment and decrease in serum CA125 levels are independent risk factors for PFS in patients, while apatinib, the length of treatment course and the location of the lesion are independent risk factors for recurrence affecting the OS of patients. The main grade 3–4 adverse events in the apatinib group were hypertension, hand-foot syndrome, and oral mucosal ulcers, and all adverse events were controllable.ConclusionApatinib was found to be both safe and effective in patients with advanced platinum-resistant relapsed EOC. More in-depth clinical research and applications should be carried out.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 1

Fig. 1

Fig. 2

Fig. 1

40854_2023_458_Article_IEq19.gif

Fig. 6